{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:23:33Z","timestamp":1749417813366},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>It is becoming increasingly important to obtain detailed diagnostic information on small-volume tissue biopsies, such as core needle biopsies. This is particularly crucial in the workup and diagnosis of classic Hodgkin lymphoma (CHL) and other morphologically similar lymphomas such as T-cell\/histiocyte-rich large B-cell lymphoma (THRLBL), where small-volume lymph node biopsies often represent the frontline tissue source, and the differential diagnosis includes a reactive process. Immunohistochemical markers could be helpful to differentiate CHL from reactive lymph node changes (RLN) in this setting. The use of programmed cell death-1 (PD-1) and its ligand (PD-L1) immunohistochemistry has historically focused on prognostic and therapeutic value when evaluating CHL. However, the present study seeks to determine the diagnostic utility of these markers in core needle biopsies of CHL (25), THRLBL (3), and RLN (31). The cases of CHL and THRLBL were previously diagnosed and confirmed with standard immunohistochemistry, allowing the utility of PD-1 and PD-L1 to be tested in this setting. Different PD-1 and PD-L1 expression patterns were observed between the reactive process of RLN and the malignant lymphomas (CHL and THRLBL). CHL cases overall showed the greatest expression of PD-L1 within the malignant Reed-Sternberg cell population, with 40% of CHL cases exhibiting &gt;50% PD-L1 expression. This degree of PD-L1 expression was not seen in the lymphocytic cell population of any RLN (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Conversely, CHL cases showed an overall lower expression of PD-1, as 96% of CHLs had &lt;5% PD-1 expression in Reed-Sternberg cells compared with only 10% expression within the lymphocytic population of RLN (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). THRLBL cases followed a similar trend to CHL. These results demonstrate that upfront PD-1 and PD-L1 immunohistochemistry can aid in the diagnosis of CHL in small-volume tissue biopsies.<\/jats:p>","DOI":"10.1097\/pas.0000000000001524","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T07:26:46Z","timestamp":1594366006000},"page":"1353-1366","source":"Crossref","is-referenced-by-count":10,"title":["PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies"],"prefix":"10.1097","volume":"44","author":[{"given":"Ashley","family":"Volaric","sequence":"first","affiliation":[{"name":"Department of Pathology, UVA Health System, Charlottesville, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Bacchi","sequence":"additional","affiliation":[{"name":"Lab Bacchi, Botucatu, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro A.","family":"Gru","sequence":"additional","affiliation":[{"name":"Department of Pathology, UVA Health System, Charlottesville, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5858\/2007-131-1033-AACOCN","article-title":"Core needle biopsy of lymphoma","volume":"131","author":"Lachar","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1309\/AJCP9ZAGKVJ8PDAX","article-title":"Needle-core biopsy in the pathologic diagnosis of malignant lymphoma showing high reproducibility among pathologists","volume":"140","author":"Hu","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCP3WZ8ZDRJQDOU","article-title":"Combined core needle biopsy and fine-needle aspiration with ancillary studies correlate highly with traditional techniques in the diagnosis of nodal-based lymphoma","volume":"135","author":"Amador-Ortiz","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V118.21.1560.1560","article-title":"The PD1\/PD-L1 axis in the classical hodgkin lymphoma microenvironment: PD-1 is rarely expressed but identifies patients with high-risk disease","volume":"118","author":"Greaves","year":"2011","journal-title":"Blood"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jcp.55.3.162","article-title":"Hodgkin\u2019s lymphoma: the pathologist\u2019s viewpoint","volume":"55","author":"Pileri","year":"2002","journal-title":"J Clin Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/ejh.13033","article-title":"Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma","volume":"100","author":"Tanaka","year":"2018","journal-title":"Eur J Haematol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","article-title":"High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome","volume":"1","author":"Hollander","year":"2017","journal-title":"Blood Adv"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cncy.21951","article-title":"Biomarkers for immune checkpoint inhibitors: the importance of tumor topography and the challenges to cytopathology","volume":"126","author":"Clark","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood.V126.23.3899.3899","article-title":"PD-L1 and PD1 expression in lymphomas","volume":"126","author":"Gatalica","year":"2015","journal-title":"Blood"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/HS9.0000000000000020","article-title":"Immune checkpoint inhibition in Hodgkin lymphoma","volume":"2","author":"Moy","year":"2018","journal-title":"Hemasphere"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2016.205","article-title":"The landscape of new drugs in lymphoma","volume":"14","author":"Younes","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1634\/theoncologist.11-4-384","article-title":"T\u2010cell\/histiocyte\u2010rich B\u2010cell lymphoma: biology, diagnosis, and management","volume":"11","author":"Abramson","year":"2006","journal-title":"Oncologist"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/his.13475","article-title":"Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells","volume":"72","author":"Sakakibara","year":"2018","journal-title":"Histopathology"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ajh.24184","article-title":"Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics","volume":"90","author":"Glimelius","year":"2015","journal-title":"Am J Hematol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1309\/AJCPFJWKQ6GTVQE6","article-title":"Large B-cell lymphomas poor in B cells and rich in PD-1+ T cells can mimic T-cell lymphomas","volume":"142","author":"Ohgami","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAS.0000000000001400","article-title":"Heterogeneity of PD-L1 expression in lung mixed adenocarcinomas and adenosquamous carcinomas","volume":"44","author":"Zito Marino","year":"2020","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:59:11Z","timestamp":1695423551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001524","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,8]]}}}